Emma V Edgar

Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor

D. Wilson, R. Cousins, J. Coates, 2007, European journal of pharmacology.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Acta crystallographica. Section F, Structural biology communications.

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

A. Hovnanian, J. Liddle, P. Thomas, 2019, Bioorganic & medicinal chemistry letters.

A potent and selective Kallikrein-5 inhibitor delivers high pharmacological activity in Netherton Syndrome patient skin.

M. Lennon, A. Hovnanian, D. Grillot, 2021, The Journal of investigative dermatology.